NEW YORK (GenomeWeb News) – BioTrove said today that Becton Dickinson will offer BioTrove’s mass spectrometry-based screening and analysis system as part of its ADME analysis services for pharmaceutical and biotech companies
Under the agreement, BD will offer BioTrove’s mass spec-based RapidFire Technology as part of its drug absorption, distribution, metabolism, and elimination services offering.
The service, which the partners said will allow customers to use the same assay in discovery and development, will initially focus on cytochrome P450 inhibition assays to assess potential drug-drug interactions.
Discovering these potential complications early on, BioTrove said, could help researchers save time and money by focusing on the most promising candidates.
BioTrove’s VP and GM, Jon Özbal, said in a statement that the service will have a seven-day turnaround.